Innovation is in our DNA

Since the foundation of Grifols in 1940, our on-going innovation has helped shape industry standards in the plasma medicines sector.

Today, our long-term R+D+i strategy combines the development of in-house initiatives and external collaborations in projects and investees whose research areas complement our core activity.

Innovation, safety and quality continue to drive us forward.

€311

million

invested in R+D+i in 2017

8

R+D+i

centers worldwide

1000

Grifols employees

work in R+D+i

  • If you stop moving forward, you stumble."

    Josep Antoni Grífols i Roig (1885-1976)

Grifols Innovation Office

Innovation is the relentless search for new health solutions for our patients. It also means our continuous commitment to improving industrial processes aiming at the utmost quality and safety of our products and services.

Grifols' commitment to innovation enables us to continue to set the standards of our industry.

We promote a comprehensive R+D+i strategy through internal and external investments. This holistic approach is articulated through the Grifols Innovation Office, responsible for evaluating and expediting the research, development and commercialization of innovative treatments, products and services.

Research areas

Grifols R+D+i projects focus on broadening the therapeutic potential of plasma proteins, enhancing the safety of blood transfusions, creating new solutions for hospital pharmacies and advancing intravenous therapies.

Read more

Project pipeline

Take a look at the portfolio of products and therapies currently in development.

Read more

AMBAR PROJECT

An ambitious research project on Alzheimer's

Grifols leads its research on Alzheimer's through an in-house project called AMBAR (Alzheimer Management by Albumin Replacement) which represents one of our most ambitious clinical trials to date.